Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) to a strong-buy rating in a research report released on Monday,Zacks.com reports.

A number of other research analysts have also weighed in on the company. Royal Bank Of Canada upped their price objective on Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Cantor Fitzgerald upped their target price on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the stock an “overweight” rating in a research report on Monday, October 13th. Finally, Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Buy” and a consensus price target of $256.60.

Ascendis Pharma A/S Trading Down 1.3%

Shares of NASDAQ:ASND traded down $2.67 during midday trading on Monday, hitting $209.49. The stock had a trading volume of 204,858 shares, compared to its average volume of 484,844. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $223.18. The stock has a 50 day moving average price of $202.65 and a two-hundred day moving average price of $185.66. The company has a market capitalization of $12.92 billion, a PE ratio of -40.61 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The company had revenue of $290.24 million for the quarter, compared to analysts’ expectations of $246.91 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. raised its position in shares of Ascendis Pharma A/S by 1.7% in the first quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock valued at $1,602,474,000 after purchasing an additional 168,752 shares during the period. Avoro Capital Advisors LLC raised its stake in Ascendis Pharma A/S by 2.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after purchasing an additional 130,000 shares during the last quarter. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 0.4% in the 3rd quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock valued at $608,481,000 after purchasing an additional 13,685 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock worth $475,970,000 after purchasing an additional 328,278 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S by 1.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,901,843 shares of the biotechnology company’s stock valued at $328,258,000 after buying an additional 23,926 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.